Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

Ultragenyx Pharmaceutical Inc. (RARE): $38.14

1.20 (-3.05%)

POWR Rating

Component Grades








Add RARE to Watchlist
Sign Up

Industry: Biotech




#150 of 355

in industry

RARE Price/Volume Stats

Current price $38.14 52-week high $54.98
Prev. close $39.34 52-week low $31.52
Day low $38.02 Volume 532,800
Day high $39.27 Avg. volume 753,039
50-day MA $44.16 Dividend yield N/A
200-day MA $42.16 Market Cap 3.17B

RARE Stock Price Chart Interactive Chart >

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.

RARE Latest News Stream

Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream

Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.

13 Most Promising Future Stocks To Buy According To Hedge Funds

In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […]

Yahoo | December 27, 2023

Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims

The Justice Department alleges Ultragenyx paid for free genetic tests for patients, and bought test results, to induce prescriptions of its drug Crysvita.

Yahoo | December 21, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 30,325 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Em

Yahoo | December 21, 2023

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hyperchole

Yahoo | December 18, 2023

Wells Fargo starts Ultragenyx coverage with overweight rating

More on Ultragenyx Pharmaceutical

Read More 'RARE' Stories Here

RARE Price Returns

1-mo -10.34%
3-mo -28.96%
6-mo -5.03%
1-year -22.73%
3-year N/A
5-year -30.57%
YTD -20.24%
2023 3.22%
2022 -44.90%
2021 -39.25%
2020 224.12%
2019 -1.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!